Home » Stocks » PBYI

Puma Biotechnology Inc. (PBYI)

Stock Price: $11.61 USD -0.36 (-3.01%)
Updated December 2, 10:29 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 461.64M
Revenue (ttm) 235.48M
Net Income (ttm) -56.20M
Shares Out 39.70M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $11.61
Previous Close $11.97
Change ($) -0.36
Change (%) -3.01%
Day's Open 11.93
Day's Range 11.42 - 11.93
Day's Volume 53,154
52-Week Range 6.28 - 14.57

More Stats

Market Cap 461.64M
Enterprise Value 464.53M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 39.70M
Float n/a
EPS (basic) -1.41
EPS (diluted) -1.43
FCF / Share 0.19
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.66%
Payout Ratio n/a
Shares Short 8.08M
Short Ratio 14.67
Short % of Float n/a
Beta 1.19
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 60.38
PS Ratio 1.96
PB Ratio 15.44
Revenue 235.48M
Operating Income -27.97M
Net Income -56.20M
Free Cash Flow 7.65M
Net Cash -2.89M
Net Cash / Share -0.07
Gross Margin 99.99%
Operating Margin -11.88%
Profit Margin -23.90%
FCF Margin 3.25%
ROA -6.78%
ROE -671.97%
ROIC -35.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 1
Overweight 0
Hold 3
Underweight 1
Sell 3

Analyst Consensus: Hold

Price Target

$9.14*
(-21.27% downside)
Low
6.00
Current: $11.61
High
15.00
Target: 9.14
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue27225127.69-------
Revenue Growth8.47%806.6%--------
Gross Profit23521622.11-------
Operating Income-39.10-94.67-292-277-240-142-54.83-74.45-10.16-0.01
Net Income-75.60-114-292-276-239-142-54.66-74.35-10.23-0.01
Shares Outstanding38.7737.9437.1733.3032.1330.0128.7021.737.754.00
Earnings Per Share-1.95-2.99-7.85-8.29-7.45-4.73-1.90-3.42-1.32-
Operating Cash Flow22.38-24.11-172-142-154-77.20-55.05-44.01-1.82-0.01
Capital Expenditures-0.31-0.61-0.43-7.28-1.18-1.29-0.63-1.06-0.69-
Free Cash Flow22.07-24.71-173-149-156-78.50-55.68-45.07-2.52-0.01
Cash & Equivalents12016586.0223422014385.1613954.44-
Total Debt12015248.48-------
Net Cash / Debt0.2713.5437.5423422014385.1613954.44-
Assets23525916625324016310415255.40-
Liabilities21722511242.9733.8445.7120.3922.791.03-
Book Value17.4634.3153.3021020611783.9912954.37-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Puma Biotechnology Inc.
Employees 269

Stock Information

Ticker Symbol PBYI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PBYI

Description

Puma Biotechnology, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.